BUY Glenmark Pharmaceuticals — IDBI Capital, 23 Jun 2026

byIDBI CapitalHorizon: 1–3 months23 Jun 2026via IDBI Capital Research Calls Telegram

Entry₹2,214Stated

Target₹2,320

Stop loss₹2,161-2.39% risk

Exit₹2,16124 Jun 2026, 12:06 pm

Stop-loss hit-2.39%

Follow IDBI Capital for new calls(28% target hit, 115 closed calls)Get alerts Watch GLENMARK for new buy/sell callsGet alerts See 2 active Short-term calls on GLENMARK See 16 active Short-term picks this week

Not investment advice; past performance doesn't guarantee future results. · Public beta — data is auto-extracted and may contain errors.

AI Assessment

Automated market context for this BUY call — facts from public sources, machine-classified. Not investment advice.

As of 8 Sept, 7:48 am IST

3 supporting2 neutral1 opposing

Supports the BUY call (3)

Glenmark Pharmaceuticals Inc., USA launched Methylene Blue Injection USP, potentially increasing revenue.

BSE · Company Update·17 Jun · 1w ago

Glenmark Pharmaceuticals Inc., USA has launched Lacosamide Injection USP, 200 mg/ 20mL (10 mg/mL), Single-Dose Vials.

BSE · Company Update·5 Jun · 3w ago

1 advisor has an active long-term BUY call on this stock

Advisor consensus · adjacent horizon·1 Jun · 3w ago

Neutral / worth noting (2)

Press Release and Management Discussion & Analysis for the Fourth Quarter ended March 31, 2026.

BSE · Company Update·29 May · 4w ago

The Board of Directors of Glenmark Pharmaceuticals Limited considered and approved audited financial results and recommended dividend.

BSE · Board Meeting·29 May · 4w ago

Weighs against the BUY call (1)

1 advisor has an active long-term SELL call on this stock

Advisor consensus · adjacent horizon·3 Feb · 5mo ago

Factor classifications are AI-generated from exchange filings, verified news feeds and market data — they can be wrong or incomplete, and are not attributed to the issuing analyst. Verify every factor via its linked original before acting. This is not investment advice.